The Peritonitis drugs in development market research report provides comprehensive information on the therapeutics under development for Peritonitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Peritonitis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Peritonitis and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Peritonitis by 11 companies/universities/institutes. The top development phase for Peritonitis is preclinical with eight drugs in that stage. The Peritonitis pipeline has nine drugs in development by companies and one by universities/ institutes. Some of the companies in the Peritonitis pipeline products market are: Pfizer, Cantargia and Nosopharm.

The key targets in the Peritonitis pipeline products market include NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain Containing 3 or NLRP3), Penicillin Binding Protein (PBP), and Penicillin Binding Protein 3 (PBP3).

The key mechanisms of action in the Peritonitis pipeline product include Penicillin Binding Protein (PBP) Inhibitor with two drugs in Preclinical. The Peritonitis pipeline products include four routes of administration with the top ROA being Intravenous and three key molecule types in the Peritonitis pipeline products market including Small Molecule, and Monoclonal Antibody.

Peritonitis overview

Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis (SBP) is the result of an infection of the fluid in peritoneal cavity. Secondary peritonitis is usually due to an infection that has spread from the digestive tract. Symptoms include abdominal bloating, nausea and vomiting, diarrhea, fatigue, fever, and chills. Treatment includes antibiotics.

For a complete picture of Peritonitis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.